NCT05378074

Brief Summary

The aim is to investigate whether opening of large conductance calcium-activated potassium (BKCa) channels induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
21

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 12, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 17, 2022

Completed
4 months until next milestone

Study Start

First participant enrolled

September 1, 2022

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

September 2, 2022

Status Verified

September 1, 2022

Enrollment Period

1.3 years

First QC Date

May 12, 2022

Last Update Submit

September 1, 2022

Conditions

Keywords

HeadachePain

Outcome Measures

Primary Outcomes (1)

  • Incidence of Migraine-Like Headache

    Difference in incidence of headache with migraine-like features (0 to 12 hours) between MaxiPost and placebo.

    12 Hours

Secondary Outcomes (1)

  • Headache Intensity Scores

    12 Hours

Study Arms (2)

MaxiPost

EXPERIMENTAL

A time- and volume-controlled infusion pump is used to administer MaxiPost by intravenous infusion over 20 minutes.

Drug: Maxipost

Placebo (isotonic saline)

PLACEBO COMPARATOR

A time- and volume-controlled infusion pump is used to administer placebo (isotonic saline) by intravenous infusion over 20 minutes.

Drug: Placebo

Interventions

Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min MaxiPost.

MaxiPost

Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).

Also known as: Isotonic Saline
Placebo (isotonic saline)

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 to 65 years of age upon entry into screening
  • History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)
  • ≥ 4 monthly headache days on average across the 3 months prior to screening Provision of informed consent prior to initiation of any study-specific activities/procedures.

You may not qualify if:

  • \> 1 mild traumatic injury to the head
  • History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)
  • History of moderate or severe injury to the head
  • History of whiplash injury
  • History of craniotomy
  • History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion
  • The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior
  • Female subjects of childbearing potential with a positive pregnancy test during any study visit
  • Cardiovascular disease of any kind, including cerebrovascular diseases
  • Hypertension (systolic blood pressure of ≥150 mmHg and/or diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day
  • Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50 mmHg)
  • Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start
  • Baseline headache intensity of \>3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)
  • Baseline headache with migraine-like features or self-reported baseline headache that mimics the subjects' usual headache with migraine-like features

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Danish Headache Center

Copenhagen, 2600, Denmark

RECRUITING

Related Publications (1)

  • Al-Khazali HM, Christensen RH, Dodick DW, Chaudhry BA, Melchior AG, Burstein R, Ashina H. Hypersensitivity to BKCa channel opening in persistent post-traumatic headache. J Headache Pain. 2024 Jun 18;25(1):102. doi: 10.1186/s10194-024-01808-0.

MeSH Terms

Conditions

Post-Traumatic HeadacheHeadachePain

Interventions

BMS204352Sodium Chloride

Condition Hierarchy (Ancestors)

Headache Disorders, SecondaryHeadache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

ChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Hakan Ashina, MD

    Danish Headache Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

May 12, 2022

First Posted

May 17, 2022

Study Start

September 1, 2022

Primary Completion

December 31, 2023

Study Completion

December 31, 2023

Last Updated

September 2, 2022

Record last verified: 2022-09

Locations